http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-505845-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7ad58d3c0b071069a8ee0cb8c8ba2e8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 1998-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9079b7931f907215290e6e19ab0aa63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80befe1826b529ea5d5fc3178a59a425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cb8344cfe4bb15a607130fa568186fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e146350b70840ce091043f9131d2459 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ef8d4aa8fde46fffe2b0cdb5b2d6c46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_352120b2107a9559243da928ad9c5e0a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a8512307534f6b757ef30e3eef783bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc62b7b6a729c9dc25557b5ffce2731c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b8ddb65a52225352cac276f37bdddcc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb3840635f781171052f9b8a2ff86dc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_011daea67d5ba153838fe7eb70e3c8d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82b0c9d56c772c66e5be8c01d6b056fa |
| publicationDate | 2003-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-505845-A |
| titleOfInvention | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| abstract | A compound of formula I where: -A is a compound of formula II, where wherein R1 is selected from the group consisting of C3-C10 alkyl, C3-C10 cycloalkyl, up to per-halosubstituted C1-C10 alkyl and up to per halosubstituted C3-C10 cycloalkyl. - B is a substituted or unsubstituted, up to tricyclic, aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 5-or 6-member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur. If B is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and Xn. -Xn comprises of n is 0-3 and each X is independently selected from the group consisting -CO2R5, -C(O)NR5R5',- C(O)R5,-NO2,-OR5,-SR5,-NR5R5',-CN, C1-C10alkyl, C2-C10 alkenyl, C1-C10 alkoxy, C3-C10 cycloalkyl, C6-C14 aryl, C7- C24 alkaryl, C3-CI3 heteroaryl, C4-C23 alkheteroaryl, substituted C1-C10 alkyl, substituted C2-10 alkenyl, substituted C1-C10 alkoxyl, substituted C3-C10 cycloalkyl, up to per halosubstituted C6-C14aryl, up to per halosubstituted C3-C13 heteroaryl, substituted C4-C23 alkheteroaryl and-Y-Ar; -Where X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO2R4, -C(O)R5, -C (O)NR5R5', -OR5, - SR5, -NR5R5', -NO2, -NR5C(O)R5', -NR5C(O)OR5' and halogen up to per-halosubstitution; -R5 and R5' are independently selected from H, C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14 aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4-C23 alkheteroaryl, up to per-halosubstituted C1- C10 alkyl, up to per halosubstituted C2-C10 alkenyl, up to perhalosubstituted C3-C10 cycloalkyl, up to perhalosubstituted C6-C14 aryl and up to per-halosubstituted C3-C13 heteroaryl. -Y is -O-, -S-, -N (R5)-, - (CH2)m-, -C(O)-, -CH(OH)-, - (CH2)mO-, -C(O)-, -CH(OH)-, -(CH2)mS-, -(CH2)mN(R5)-, - O(CH2)m-, -CHXa-, -CXa2-, -S-(CH2)m- and -N(R5)(CH2)m. -m = 1-3, and Xa is halogen. -Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Zn1 , wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of-CN, -C(O)NR5,-CO2R5, -C(O)NR5', -NO2-, OR5, -SR5, -NR5R5', -NR5C(O)OR5', -NR5C(O)R5', - NR5C(O)NR5', C1-C10 alkyl, C3-C10 cycloalkyl, C6-C14 aryl, C3-C13 heteroaryl, C7-CC24 alkaryl and substituted C4-C23 alkheteroaryl. -Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of -CN, -CO2R5, -C(O)NR5R5', -OR5, -SR5, -NO2, - NR5R5', -NR5C(O)R5' and-NR5C(O)OR5'. -R2 is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to perhalosubstitution, and Vn, wherein n = 0-3 and each V is independently selected from the group consisting -CO2R5,-C(O)NR5R5',-OR5,-SR5,-NR5R5',- C(O)R5,-CN, -SO2R5,-SOR5,-NR5C(O)R5',-NO2,C1-C10 alkyl, C3- OC(O)NR5R5', -NR5C(O)OR5', C6-C14 aryl, C3-C13 heteroaryl, C7-C24 alkaryl, C4-C24 alkheteroaryl, C10 cycloalkyl, substituted substituted C3-C10 cycloalkyl,substituted C6-C14 aryl, substituted C3-C13 heteroaryl, substituted C7-C24 alkheteroaryl. V is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to per -CO2R5,- C(O)R5,halosubstitution,-CN, -OR5,-SR5,-NR5R5', and-NO2;- NR5C(O)R5',-NR5C(O)OR5' wherein R5 and R5' are each independently as defined above. Used in the treatment of diseases mediated by raf-kinase. |
| priorityDate | 1997-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 222.